Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension
暂无分享,去创建一个
Barry J. Davis | Jackson T. Wright | P. Whelton | H. Black | N. Wong | J. Basile | R. Dart | U. Thadani | C. Nwachuku | J. Barzilay | Charles L. Baimbridge | H. Marginean | J. Wright
[1] B. Davis,et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2006, Archives of internal medicine.
[2] S. Yusuf,et al. Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.
[3] W. Elliott. Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials , 2006 .
[4] M. Schachter. Review: Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts , 2005 .
[5] T. Giles,et al. Pathophysiologic, Diagnostic, and Therapeutic Aspects of the Metabolic Syndrome , 2005, Journal of clinical hypertension.
[6] D. E. Mathis,et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2005, Archives of internal medicine.
[7] Neil Chapman,et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.
[8] Alan C. Wilson,et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. , 2005, The American journal of cardiology.
[9] T. Kurtz,et al. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system , 2004, Journal of hypertension.
[10] R. Miatello,et al. Mechanisms of cardiovascular changes in an experimental model of syndrome X and pharmacological intervention on the renin-angiotensin-system. , 2004, Current vascular pharmacology.
[11] R. Schall,et al. Old antihypertensives and new diabetes , 2004, Journal of hypertension.
[12] Michael A. Weber. Hypertension, the Metabolic Syndrome, and the Risk of Developing Diabetes: Is It Time to Change the Guidelines? , 2004, Journal of clinical hypertension.
[13] N. Garbacki,et al. The kallikrein‐kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity , 2004, Diabetes/metabolism research and reviews.
[14] Arvind Shah,et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). , 2004, Diabetes care.
[15] J. Morrow,et al. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. , 2004, American journal of hypertension.
[16] V. Hasselblad,et al. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. , 2004, The American journal of cardiology.
[17] S. Grundy,et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[18] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.
[19] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[20] Carl J Pepine,et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.
[21] L. Wilkins. Diuretic Versus &agr;-Blocker as First-Step Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2003 .
[22] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[23] W. Dietz,et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.
[24] S. Yusuf,et al. Ramipril and the development of diabetes. , 2001, JAMA.
[25] David Roth,et al. A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .
[26] F. Nieto,et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .
[27] L. Niskanen,et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.
[28] C. E. Machado,et al. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 1998, Hypertension.
[29] Michael A. Proschan,et al. Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 1996 .
[30] M. Laakso,et al. Increased risk of non‐insulin-dependent diabetes mellitus in elderly hypertensive subjects , 1994, Journal of hypertension.
[31] H. Parving. Excess mortality associated with diuretic therapy in diabetes mellitus. , 1992, Archives of internal medicine.
[32] A. Krolewski,et al. Excess mortality associated with diuretic therapy in diabetes mellitus. , 1991, Archives of internal medicine.